Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2146312 Target Snapshot

Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN · SINGLE PROTEIN · Homo sapiens

8,367Compounds
15Assays
1Approved Drugs
55.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q14191. Use UniProt Q14191 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q14191 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN as ChEMBL target CHEMBL2146312, mapped to UniProt Q14191. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2146312
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14191
Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN is the right protein anchor across sources, using UniProt Q14191 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
UniProt AccessionQ14191
Component TypeProtein
Sequence Length1432 aa

Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN, mapped to UniProt Q14191. Sequence length is 1432 aa.

Mapped IDQ14191
Review nameBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC5055.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1091250 6.7 IC50 200.0 Approved
CHEMBL1968672 6.64 IC50 230.0 Preclinical
CHEMBL2426164 5.96 IC50 1100.0 Preclinical
CHEMBL2426190 5.8 IC50 1600.0 Preclinical
CHEMBL2426169 5.66 IC50 2200.0 Preclinical
CHEMBL1353989 5.64 IC50 2300.0 Preclinical
CHEMBL5564300 5.64 IC50 2305.0 Preclinical
CHEMBL2426168 5.57 IC50 2700.0 Preclinical
CHEMBL2426161 5.54 IC50 2900.0 Preclinical
CHEMBL1374426 5.52 IC50 3000.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
9
5.5
0
6.0
2
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

INDIGOTINDISULFONATE
CHEMBL1091250
Approved 2022
Assay Landscape

Assay Landscape

15
Total Assays
42
Tested Compounds
2
Assay Types
Binding — 13 assays, 42 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 28 4.6
single protein format 5 13 5.4
assay format 1 1 5.5
Functional — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine